Copertina

Letter: Increased Prevalence of Visceral Obesity in Nonresponder Patients With Primary Biliary Cholangitis Based on Computed Tomography—Authors' Reply

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Conrado Fernandez‐Rodriguez, Maria Hernandez‐Perez, Antonio Olveira
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Letter: Increased Prevalence of Visceral Obesity in Nonresponder Patients With Primary Biliary Cholangitis Based on Computed Tomography
di: Bo Li, et al.
Pubblicazione: (2024)

Letter: Incremental Value and Stratified Interpretation of Dual Autoantibody Positivity in Primary Biliary Cholangitis. Authors' Reply
di: Hong‐Li Liu, et al.
Pubblicazione: (2026)

Letter: Myokines Are Also Associated With Disease Course in Primary Biliary Cholangitis
di: Leyu Zhou, et al.
Pubblicazione: (2024)

Letter: Incremental Value and Stratified Interpretation of Dual Autoantibody Positivity in Primary Biliary Cholangitis
di: Ao Gao, et al.
Pubblicazione: (2026)

Lymphocyte‐to‐Monocyte Ratio as a Predictor of Recompensation in Patients With Decompensated Primary Biliary Cholangitis
di: Huiying Lin, et al.
Pubblicazione: (2025)

Letter on ‘Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis’
di: Yi Pei, et al.
Pubblicazione: (2025)

A Nationwide Assessment of Anticholestatic Therapy Uptake in Patients With Primary Biliary Cholangitis: Opportunities for Optimisation
di: Ellen Werner, et al.
Pubblicazione: (2026)

Review Article: Targeting Peroxisome Proliferator‐Activated Receptors in Primary Biliary Cholangitis
di: Jörn M. Schattenberg, et al.
Pubblicazione: (2026)

Research Communication: Real‐World Clinical Experience With Seladelpar in Primary Biliary Cholangitis
di: Selena Z. Kuo, et al.
Pubblicazione: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
di: Virginia Solitano, et al.
Pubblicazione: (2024)

Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis—Time to change our targets? Authors' reply
di: C. M. Fernández‐Rodríguez, et al.
Pubblicazione: (2024)

Longitudinal Relationship Between Elevated Liver Biochemical Tests and Negative Clinical Outcomes in Primary Biliary Cholangitis: A Population‐Based Study
di: Kris V. Kowdley, et al.
Pubblicazione: (2025)

Long‐Term Use of Fenofibrate as Second‐Line Therapy in Primary Biliary Cholangitis: A Retrospective Study
di: Mariko Maxwell, et al.
Pubblicazione: (2026)

Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis
di: Nadir Abbas, et al.
Pubblicazione: (2025)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease—Authors' Reply
di: Isabel Carbery, et al.
Pubblicazione: (2024)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis—Authors' Reply
di: Francisco Idalsoaga, et al.
Pubblicazione: (2025)

Seladelpar Improved Itch, Itch‐Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial
di: Cynthia Levy, et al.
Pubblicazione: (2026)

Letter on ‘Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis’: Authors' Reply
di: Lukas Burghart, et al.
Pubblicazione: (2026)

Letter: Thiopurines the Silent Workhorse for Many Patients After a Flare of Ulcerative Colitis. Authors' Reply
di: Ankit Kumar, et al.
Pubblicazione: (2026)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’. Authors' Reply
di: Christian Labenz, et al.
Pubblicazione: (2026)

Letter: Toward Intra‐Class Switching With JAK Inhibitors? Authors' Reply
di: Shintaro Akiyama, et al.
Pubblicazione: (2025)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations. Authors' Reply
di: J. M. Schattenberg, et al.
Pubblicazione: (2026)

Letter: Helicobacter pylori and Eosinophilic Oesophagitis—Lost in Definition? Authors' Reply
di: Irene Spinelli, et al.
Pubblicazione: (2025)

Letter: Addressing Gaps in Hospital‐Based Hepatitis C Screening—Insights and Recommendations. Authors' Reply'
di: Alberto Ferrarese, et al.
Pubblicazione: (2025)

The overlap with metabolic dysfunction‐associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis
di: María Hernández‐Pérez, et al.
Pubblicazione: (2024)

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients with Inflammatory Bowel Disease. Author's Reply
di: A. B. Fons, et al.
Pubblicazione: (2026)

Letter: Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV—Authors' Reply
di: Juan Macias, et al.
Pubblicazione: (2025)

Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply
di: Nina Dominik, et al.
Pubblicazione: (2024)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations. Authors' Reply
di: Mohamed El‐Kassas, et al.
Pubblicazione: (2025)

Dual Positivity for AMA / AMA ‐ M2 and Anti‐gp210/sp100 Shows Highest Diagnostic Value for Primary Biliary Cholangitis
di: Hong‐Li Liu, et al.
Pubblicazione: (2026)

Editorial: Obesity and Outcomes on Advanced Therapy in Ulcerative Colitis—The Fat of the Matter: Authors' Reply
di: Aakash Desai, et al.
Pubblicazione: (2025)

Letter on ‘Meta‐Analysis: Mortality Trends and Risk Factors in Severe Alcohol‐Associated Hepatitis’—Authors' Reply
di: Francisco Idalsoaga, et al.
Pubblicazione: (2025)

Letter: Refining Mortality Estimates in Severe Alcohol–Associated Hepatitis—Addressing Heterogeneity and Prognostic Assessment. Authors' Reply
di: Francisco Idalsoaga, et al.
Pubblicazione: (2025)

Letter: Double PBC ‐Related Autoantibody Positivity—How Essential Is It for Diagnosis? Authors' Reply
di: Hong‐Li Liu, et al.
Pubblicazione: (2026)

Letter: Beyond Association—Operationalising PRS ‐5 for Hepatocellular Carcinoma Surveillance. Authors' Reply
di: Yu‐Sheng Lin, et al.
Pubblicazione: (2026)

Letter: Amino Acid Imbalance and Mortality in Cirrhosis—Interpretation and Methodological Considerations. Authors' Reply
di: Yuki Utakata, et al.
Pubblicazione: (2026)

Letter: Enhancing Risk‐Adapted Colorectal Cancer Screening for People With Diabetes—Authors' Reply
di: Teresa Seum, et al.
Pubblicazione: (2025)

Letter: A Patient Centric Approach to Tapering Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis. Authors' Reply
di: Amol N. Patil, et al.
Pubblicazione: (2026)

Editorial: Evaluating the Prevalence of Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinaemia—Authors' Reply
di: Maral Amangurbanova, et al.
Pubblicazione: (2024)

Letter: Drug‐Induced Autoimmune‐Like Hepatitis—A Trigger on the Disease Spectrum. Authors' Reply
di: Pinelopi Arvaniti, et al.
Pubblicazione: (2025)